U.S. Pharmaceutical Markets: Expenditures, Health Insurance, New Products and Generic Prescribing from 1960 to 2016

References

• Acemoglu, Daron, and Joshua Linn. 2004. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Quarterly Journal of Economics 119 (3): 1049–90.
   Web of Science ®Google Scholar
• Akaike, Hirotugu. 1977. On Entropy Maximization Principle. In Applications of Statistics, edited by Paruchuri R. Krishniah, 27–42. Amsterdam: North Holland.
   Google Scholar
• Amiri, Arshia, and Bruno Ventelou. 2011. Granger Causality between Total Expenditure on Health and GDP in OECD: Evidence from the Toda-Yamamoto Approach. Economics Letters 116 (3): 541–544. doi:10.1016/j.econlet.2012.04.040.
   Web of Science ®Google Scholar
• Assistant Secretary for Planning and Evaluation (ASPE). 2016. Understanding Recent Trends in Generic Drug Prices. January 27. Accessed November 2018. https://aspe.hhs.gov/system/files/pdf/175071/GenericsDrugpaperr.pdf
   Google Scholar
• Bauer, Hans H., and Marc Fischer. 2000. Product Life Cycle Patterns for Pharmaceuticals and Their Impact on R&D Profitability of Late Mover Products. International Business Review 9 (6): 703–725. doi:10.1016/S0969-5931(00)00028-7.
   Google Scholar
• Baumöhl, Eduard, and Stefan Lyócsa. 2009. Stationarity of Time Series and the Problem of Spurious Regression. Munich Personal RePEc Archive Paper, No. 27926. Accessed June 2018. https://mpra.ub.uni-muenchen.de/27926/
   Google Scholar
• Berndt, Ernst R. 2001. The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment? Health Affairs 20 (2): 100–114. doi:10.1377/hlthaff.20.2.100.
   Web of Science ®Google Scholar
• Berndt, Ernst R., and Murray L. Aitken. 2011. Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in The Quarter Century after the 1984 Waxman-Hatch Legislation. International Journal of the Economics of Business 18 (2): 177–201.
   Google Scholar
• Bureau of Labor Statistics. 2018. Consumer Price Index for All Urban Consumers (CPI-U): U. S. city average, by detailed expenditure category. Accessed September 2018. https://www.bls.gov/news.release/cpi.t02.htm
   Google Scholar
• Bureau of Labor Statistics. 2011. The Pharmaceutical Industry: An Overview of CPI, PPI, and IPP Methodology. Accessed October 2018. https://www.bls.gov/ppi/pharmpricescomparison.pdf
   Google Scholar
• Carrion-I-Silvestre, Lluis J. 2005. Health Care Expenditure and GDP: Are They Broken Stationary? Journal of Health Economics 24 (5): 839–854. doi:10.1016/j.jhealeco.2005.01.001.
   PubMed Web of Science ®Google Scholar
• Catlin, Aaron C., and Cathy A. Cowan. 2015. History of Health Spending in the United States, 1960-2013. Special report written for the Center for Medicare and Medicaid Services. Accessed October 2017. https://www.cms.gov/Research-Statistics-Dataand-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/HistoricalNHEPaper.pdf
   Google Scholar
• Center for Medicare and Medicaid Services. 2014. National Health Expenditure Accounts: Methodology Paper, 2014. Accessed June 2018. https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/downloads/dsm-14.pdf
   Google Scholar
• Center for Medicare and Medicaid Services. 2018. National Health Expenditures by Type of Services and Source of Funds, CY 1960-2016. Accessed June 2018. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.html
   Google Scholar
• Comanor, William S. 1965. Research and Technical Change in the Pharmaceutical Industry. The Review of Economics and Statistics 47 (2): 182–190. doi:10.2307/1924065.
   Web of Science ®Google Scholar
• Danzon, Patricia M., and Mark V. Pauly. 2002. Health Insurance and the Growth in Pharmaceutical Expenditures. The Journal of Law and Economics 45 (S2): 587–613. doi:10.1086/368005.
   Google Scholar
• Danzon, Patricia M., and Michael F. Furukawa. 2008. International Prices and Availability of Pharmaceuticals in 2005. Health Affairs 27 (1): 221–233. doi:10.1377/hlthaff.27.1.221.
   Web of Science ®Google Scholar
• Dubois, Pierre, Olivier de Mouzon, Fiona M. Scott, and Paul Seabright. 2015. Market Size and Pharmaceutical Innovation. The Rand Journal of Economics 46 (4): 844–871.
   Google Scholar
• DeRuiter, Jack, and Pamela L. Holston. 2012. Drug Patent Expirations and the Patent Cliff. U.S. Pharmacist 37 (6): 12–20.
   Google Scholar
• Dickey, David A., and Wayne A. Fuller. 1981. Likelihood Ratio Statistics for Autoregressive Time Series with a Unit Root. Econometrica 49 (4): 1057–1072. doi:10.2307/1912517.
   Web of Science ®Google Scholar
• DiMasi, Joe A., Henry G. Grabowski, and Ronald W. Hansen. 2016. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics 47 (3): 20–33.
   PubMed Web of Science ®Google Scholar
• Duggan, Mark, Patrick Healy, and Fiona S. Morton. 2008. Providing Prescription Drug Coverage to the Elderly: America’s Experiment with Medicare Part D. Journal of Economic Perspectives 22 (4): 69–92. doi:10.1257/jep.22.4.69.
   PubMed Web of Science ®Google Scholar
• Duggan, Mark, and Fiona S. Morton. 2010. The Effect of Medicare Part D on Pharmaceutical Prices and Utilization. American Economic Review 100 (1): 590–607. doi:10.1257/aer.100.1.590.
   PubMed Web of Science ®Google Scholar
• Duggan, Mark, and Fiona S. Morton. 2011. The Medium-Term Impact of Medicare Part D on Pharmaceutical Prices. American Economic Review 101 (3): 387–392. doi:10.1257/aer.101.3.387.
   Web of Science ®Google Scholar
• Fan, Jianging, and Qiwei Yao. 2015. The Elements of Financial Econometrics. New York: Cambridge University Press.
   Google Scholar
• Federal Reserve Bank of St. Louis, Economic Research Bureau. 2018. Gross Domestic Product: Implicit Price Deflator (GDPDEF). Accessed June 2018. https://fred.stlouisfed.org/series/GDPDEF
   Google Scholar
• Fischer, Marc, Peter S. H. Leeflang, and Peter C. Verhoef. 2010. Drivers of Peak Sales for Pharmaceutical Brands. Quantitative Marketing and Economics 8 (4): 429–460. doi:10.1007/s11129-010-9089-5.
   Web of Science ®Google Scholar
• Food and Drug Administration. 2016. CY 2015 CDER Drug and Biologic Calendar Year Approvals as of December 31, 2015. Accessed July 2018. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApproval Reports/NDAandBLAApprovalReports/UCM486442.pdf
   Google Scholar
• Food and Drug Administration. 2018. Drugs@FDA: FDA Approved Drug Products. Accessed August 2018. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
   Google Scholar
• Frank, Richard G., and Joseph P. Newhouse. 2008. Should Drug Prices Be Negotiated under Part D of Medicare? And If So, How? Health Affairs 27 (1): 33–43. doi:10.1377/hlthaff.27.1.33.
   Web of Science ®Google Scholar
• Frank, Richard G., and Richard Zeckhauser. 2017. A Framework for Negotiation in Medicare Part D. Hutchins Center Working Paper 28. Washington, DC: The Hutchins Center on Fiscal and Monetary Policy at the Brookings Institution.
   Google Scholar
• Frech, Harry E., III, and Paul B. Ginsburg. 1975. Imposed Health Insurance in Monopolistic Markets, a Theoretical Analysis. Economic Inquiry 13 (1): 55–70. doi:10.1111/j.1465-7295.1975.tb01103.x.
   Web of Science ®Google Scholar
• Gibson, Teresa B., Ronald J. Ozminkowski, and Ronald Z. Goetzel. 2005. The Effects of Prescription Drug Cost Sharing: A Review of the Evidence. The American Journal of Managed Care 11 (11): 730–740.
   PubMed Web of Science ®Google Scholar
• Grabowski, Henry, and John Vernon. 1992. Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Drug Act. The Journal of Law and Economics 35 (2): 331–350. doi:10.1086/467257.
   Web of Science ®Google Scholar
• Grabowski, Henry, and John Vernon. 2000. The Determinants of Pharmaceutical Research and Development Expenditures. Journal of Evolutionary Economics 10 (1-2): 201–215. doi:10.1007/s001910050012.
   Web of Science ®Google Scholar
• Grabowski, Henry, John Vernon, and Joseph A. DiMasi. 2002. Return on Research and Development for 1990s New Drug Introductions. PharmacoEconomics 20 (Supplement 3): 11–29.
   PubMedGoogle Scholar
• Granger, Clive W. J. 1969. Investigating Causal Relations by Econometric Models and Cross-Spectral Methods. Econometrica 37 (3): 424–436. doi:10.2307/1912791.
   Web of Science ®Google Scholar
• Hoover, Kevin D. 2001. Causality in Macroeconomics. Cambridge, England: Cambridge University Press.
   Google Scholar
• Huskamp, Haiden A., Patricia A. Deverka, Arnold M. Epstein, Robert S. Epstein, Kimberly A. McGuigan, and Richard G. Frank. 2003. The Effect of Incentive-Based Formularies on Prescription Drug Utilization and Spending. New England Journal of Medicine 349 (23): 2224–2232. doi:10.1056/NEJMsa030954.
   PubMed Web of Science ®Google Scholar
• IQVIA. 2017. Medicines Use and Spending in the U.S.: A Review of 2016 and Outlook to 2021. Institute Report, May 4.
   Google Scholar
• Jacobs, Rodney L., Edward E. Leamer, and Michael P. Ward. 1979. Difficulties with Testing for Causation. Economic Inquiry 17 (3): 401–413. doi:10.1111/j.1465-7295.1979.tb00538.x.
   Web of Science ®Google Scholar
• Jewell, Todd, Junsoo Lee, Margie Tieslau, and Mark Strazicich. 2003. Stationarity of Health Expenditures and GDP: Evidence from Panel Unit Root Tests with Heterogeneous Structural Breaks. Journal of Health Economics 22 (2): 313–323. doi:10.1016/S0167-6296(02)00122-4.
   PubMed Web of Science ®Google Scholar
• Joyce, Geoffrey F., Jose J. Escarce, Matthew D. Solomon, and Dana P. Goldman. 2002. Employer Drug Benefit Plans and Spending on Prescription Drugs. JAMA 288 (14): 1733–1739. doi:10.1001/jama.288.14.1733.
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. 2003. Medicare and Prescription Drug Spending Chartpack. Menlo Park, CA: Kaiser Family Foundation.
   Google Scholar
• Kokemuller, Neil. 2018. How Can Shorter Product Life Cycles Be an Obstacle? October 11. Accessed November 2018. https://yourbusiness.azcentral.com/can-shorter-product-life-cycles-obstacle-25951.html
   Google Scholar
• Leamer, Edward E. 1985. Vector Autoregressions for Causal Inference. In Understanding Monetary Regimens, edited by Karl Brunner and Alan Metzler, 255–304. Stanford, CA: The Hoover Institution Press.
   Google Scholar
• Maddala, Gangadharrao S. 1992. Introduction to Econometrics. 2nd ed. New York: Macmillian Publishing.
   Google Scholar
• Murray, John E. 2007. Origins of American Health Insurance: A History of Industrial Sickness Funds. New Haven, CT: Yale University Press.
   Google Scholar
• National Academy of Sciences. 2018. Making Medicines Affordable: A National Imperative. Washington, DC: The National Academies Press.
   Google Scholar
• Nordhaus, William D. 1969. An Economic Theory of Technological Change. American Economic Review 59 (2): 18–28. doi:10.1257/aer.109.6.1991.
   Web of Science ®Google Scholar
• Oliver, Thomas R., Philip R. Lee, and Helen L. Lipton. 2004. A Political History of Medicare and Prescription Drug Coverage. The Milbank Quarterly 82 (2): 283–354. doi:10.1111/j.0887-378X.2004.00311.x.
   PubMed Web of Science ®Google Scholar
• Papanicolas, Irene, and Alistair McGuire. 2017. Measuring and Forecasting Quality in English Hospitals. Journal of the Royal Statistical Society: Series A (Statistics in Society) 180 (2): 409–432. doi:10.1111/rssa.12203.
   Web of Science ®Google Scholar
• Pauly, Mark V. 1968. The Economics of Moral Hazard: Comment. The American Economic Review 58 (3): 531–537.
   Web of Science ®Google Scholar
• Pauly, Mark V. 1974. Over-Insurance and Public Provision of Insurance: The Roles of Moral Hazard and Adverse Selection. The Quarterly Journal of Economics 88 (1): 44–62. doi:10.2307/1881793.
   Web of Science ®Google Scholar
• Pauly, Mark V. 2012. Insurance and Drug Spending. In Oxford Handbook of the Economics of the Biopharmaceutical Industry, edited by Patricia Danzon and Sean Nicholson, 336–364. New York: Oxford University Press.
   Google Scholar
• Pharmaceutical Research and Manufacturers of America (PhRMA). 2015. 2015 Profile: Biopharmaceutical Research Industry. Washington, DC: PhRMA.
   Google Scholar
• Scherer, Frederic M. 2001. The Link between Gross Profitability and Pharmaceutical R&D Spending. Health Affairs 20 (5): 216–220.
   Web of Science ®Google Scholar
• Schweitzer, Stuart O., and Z. John Lu. 2018. Pharmaceutical Economics and Policy: Perspectives, Promises, and Problems. 3rd ed. New York: Oxford University Press.
   Google Scholar
• Sims, Christopher A. 1972. Money, Income, and Causality. American Economic Review 62 (4): 450–552. doi:10.1257/aer.103.2.563.
   Web of Science ®Google Scholar
• U.S. Census Bureau. 2018. Population. Accessed October 2017. https://www.census.gov/topics/population.html
   Google Scholar
• Weisbrod, Burton A. 1991. The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment. Journal of Economic Literature 29 (2): 523–552.
   Web of Science ®Google Scholar
• Zellner, Arnold. 1988. Causality and Causal Laws in Economics. Journal of Econometrics 39 (1-2): 7–21. doi:10.1016/0304-4076(88)90038-3.
   Web of Science ®Google Scholar